Basit öğe kaydını göster

dc.contributor.authorYalin, Ayse S.
dc.contributor.authorGuven, Mehmet
dc.contributor.authorGuven, Gülgün
dc.contributor.authorAltiparmak, Mehmet R.
dc.contributor.authorTunckale, Aydin
dc.contributor.authorBatar, Bahadir
dc.contributor.authorTrabulus, Sinan
dc.date.accessioned2021-03-05T17:48:50Z
dc.date.available2021-03-05T17:48:50Z
dc.date.issued2013
dc.identifier.citationGuven G., Altiparmak M. R. , Trabulus S., Yalin A. S. , Batar B., Tunckale A., Guven M., "Relationship Between Genomic Damage and Clinical Features in Dialysis Patients", GENETIC TESTING AND MOLECULAR BIOMARKERS, cilt.17, ss.202-206, 2013
dc.identifier.issn1945-0265
dc.identifier.otherav_c7592fe1-98a5-4db7-9591-c84ab1170137
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/132138
dc.identifier.urihttps://doi.org/10.1089/gtmb.2012.0301
dc.description.abstractPatients with end-stage renal disease display enhanced genomic damage. We investigated the presence of genomic damage in the peripheral lymphocytes by using the micronucleus (MN) test and the factors associated with the MN frequency in hemodialysis (HD) and peritoneal dialysis (PD) patients. We studied 121 dialysis patients (60 HD and 61 PD) and 129 age-and gender-matched healthy controls. The MN analysis, used as a biomarker of chromosomal/DNA damage, was performed in peripheral lymphocytes by the cytokinesis-block method. Univariate analysis showed a significantly higher MN frequency in all patients in comparison with the controls (7.6% +/- 0.3% vs. 4.9% +/- 0.2%, respectively, p < 0.001). Significantly higher frequency of MN was observed in both HD and PD patients compared to controls (7.7% +/- 0.5% vs. 4.9% +/- 0.2%, p < 0.001 and 7.5% +/- 0.5% vs. 4.9% +/- 0.2%, p < 0.001, respectively). Multivariate analysis was performed, and it showed that the low-density lipoprotein level was the only independent determinant of increasing MN frequency in our patients (beta = 0.16, t = 2.172, p < 0.05). There is no significant difference in terms of genomic damage between two dialysis modalities, which suggests that PD may not be a more reliable choice in terms of genomic damage.
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectTıbbi Genetik
dc.subjectSitogenetik
dc.subjectTemel Bilimler
dc.subjectGENETİK VE HAYAT
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectBİYOKİMYA VE MOLEKÜLER BİYOLOJİ
dc.subjectMoleküler Biyoloji ve Genetik
dc.titleRelationship Between Genomic Damage and Clinical Features in Dialysis Patients
dc.typeMakale
dc.relation.journalGENETIC TESTING AND MOLECULAR BIOMARKERS
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume17
dc.identifier.issue3
dc.identifier.startpage202
dc.identifier.endpage206
dc.contributor.firstauthorID54445


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster